These results suggest that interference with eIF5B expression can enhance the killing capability of PBMCs on prostate cancer cells, while PD-L1 overexpression based on the interference of eIF5B expression may weaken such enhancement. This evidence concerns the gene CD274 and prostate carcinoma.